Clinical Impact of the Capacity-Motivation-Opportunity Pharmacist-Led Intervention in People Living with HIV in Spain, 2019–2020

References

• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–1426. doi:10.1016/S0140-6736(08)60423-7
   PubMed Web of Science ®Google Scholar
• Palepu A, Sun H, Kuyper L, Schechter MT, O’Shaughnessy MV, Anis AH. Predictors of early hospital readmission in HIV-infected patients with pneumonia. J Gen Intern Med. 2003;18(4):242–247. doi:10.1046/j.1525-1497.2003.20720.x
   PubMed Web of Science ®Google Scholar
• McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E, A Pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients. Pharmacotherapy. 2017;37(12):1498–1506. doi:10.1002/phar.2043
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Gill TK, Sherman EM, McNicholl IR, Hawkins B. ASHP guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73(7):468–494. doi:10.2146/ajhp150623
   PubMed Web of Science ®Google Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Health Syst Pharm. 1990;47(3):533–543. doi:10.1093/ajhp/47.3.533
   Web of Science ®Google Scholar
• Urano K, Ishibashi M, Matsumoto T, et al. Impact of physician-pharmacist collaborative protocol-based pharmacotherapy management for HIV outpatients: a retrospective cohort study. J Pharm Health Care Sci. 2020;6:9. doi:10.1186/s40780-020-00165-9
   PubMed Web of Science ®Google Scholar
• Margulis A, Uhlyar S, Chin-Beckford N, et al. Clinical pharmacist input on HIV management may improve antiretroviral prescribing for psychiatric patients. Am J Health Syst Pharm. 2021;78(Supplement_1):S10–S5. doi:10.1093/ajhp/zxaa310
   PubMed Web of Science ®Google Scholar
• Morillo-Verdugo R, Calleja-Hernández MÁ, de Las Aguas Robustillo-Cortés M. A new pharmaceutical care concept: more capable, motivated, and timely. Hosp Pharm. 2019;54(6):348–350. doi:10.1177/0018578719867657
   PubMed Web of Science ®Google Scholar
• Morillo-Verdugo R, Robustillo-Cortes MA, Manzano Garcia M, Almeida-Gonzalez CV. Influence of pharmacist intervention, based on CMO model, to improve activation in HIV patients. Rev Esp Quimioter. 2019;32(1):40–49.
   PubMed Web of Science ®Google Scholar
• Morillo-Verdugo R, Robustillo-Cortés MA, Martín-Conde MT, et al. Effect of a structured pharmaceutical care intervention versus usual care on cardiovascular risk in HIV patients on antiretroviral therapy: INFAMERICA study. Ann Pharmacother. 2018;52(11):1098–1108. doi:10.1177/1060028018778045
   PubMed Web of Science ®Google Scholar
• Socieda Española de Farmacia Hospitalaria (SEFH). El modelo CMO en consultas externas de Farmacia Hospitalaria [The CMO pharmaceutical care model in hospital pharmacy outpatient consultations]; 2016. Available from: https://www.sefh.es/sefhpdfs/Libro_CMO.pdf. Accessed January 20, 2022. Spanish.
   Google Scholar
• Morillo-Verdugo R, Martinez-Sesmero JM, Lazaro-Lopez A, Sanchez-Rubio J, Navarro-Aznarez H, DeMiguel-Cascon M. Development of a risk stratification model for pharmaceutical care in HIV patients. Farm Hosp. 2017;41(3):346–356. doi:10.7399/fh.2017.41.3.10655
   PubMed Web of Science ®Google Scholar
• Morillo Verdugo R, Villarreal Arevalo AL, Alvarez De Sotomayor M, Robustillo Cortes ML. Development of a taxonomy for pharmaceutical interventions in HIV+ patients based on the CMO model. Farm Hosp. 2016;40(n06):544–568. doi:10.7399/fh.2016.40.6.10567
   PubMedGoogle Scholar
• Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–1026. doi:10.1111/j.1475-6773.2004.00269.x
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622. doi:10.1001/jamainternmed.2013.3728
   PubMed Web of Science ®Google Scholar
• Drozd DR, Kitahata MM, Althoff KN, et al. Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. J Acquir Immune Defic Syndr. 2017;75(5):568–576. doi:10.1097/QAI.0000000000001450
   PubMed Web of Science ®Google Scholar
• Masia M, Perez-Cachafeiro S, Leyes M, et al. Riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana en España [Cardiovascular risk in human immunodeficiency virus-infected patients in Spain]. CoRIS cohort, 2011]. Enferm Infecc Microbiol Clin. 2012;30(9):517–527. Spanish. doi:10.1016/j.eimc.2012.02.014
   PubMed Web of Science ®Google Scholar
• Russell E, Albert A, Cote H, et al. Rate of dyslipidemia higher among women living with HIV: a comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. HIV Med. 2020;21(7):418–428. doi:10.1111/hiv.12843
   PubMed Web of Science ®Google Scholar
• Gelpi M, Afzal S, Lundgren J, et al. Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglyceridemia, but not of hypertension, in people living with Human Immunodeficiency Virus (HIV): results from the Copenhagen comorbidity in HIV infection study. Clin Infect Dis. 2018;67(4):579–586. doi:10.1093/cid/ciy146
   PubMed Web of Science ®Google Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8(6):737–741. doi:10.1161/01.atv.8.6.737
   PubMedGoogle Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. doi:10.1161/01.cir.79.1.8
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. doi:10.1001/jama.2009.1619
   PubMed Web of Science ®Google Scholar
• Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97(2):E248–56. doi:10.1210/jc.2011-1846
   PubMed Web of Science ®Google Scholar
• Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351(6278):1166–1171. doi:10.1126/science.aad3517
   PubMed Web of Science ®Google Scholar
• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572–580. doi:10.1016/S0140-6736(12)60312-2
   PubMed Web of Science ®Google Scholar
• Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38(32):2478–2486. doi:10.1093/eurheartj/ehx163
   PubMed Web of Science ®Google Scholar
• Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc. 2014;3(2):e000519. doi:10.1161/JAHA.113.000519
   PubMed Web of Science ®Google Scholar
• Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. doi:10.1136/bmj.g4379
   PubMed Web of Science ®Google Scholar
• Marshall R, Beach MC, Saha S, et al. Patient activation and improved outcomes in HIV-infected patients. J Gen Intern Med. 2013;28(5):668–674. doi:10.1007/s11606-012-2307-y
   PubMed Web of Science ®Google Scholar